Showing results (1-10 of 50) with videos related to
Sort By:
Pageof 5
Current Opinion in Endocrinology, Diabetes, and Obesity|January 23, 2022
Long-acting amylin analogues for the management of obesityDavid S Mathiesen, Jonatan I Bagger, Filip K KnopThe Review of Diabetic Studies : RDS|January 21, 2012
Therapy for obesity based on gastrointestinal hormonesJonatan I Bagger, Mikkel Christensen, Filip K Knop, et al.The Review of Diabetic Studies : RDS|January 21, 2012
The alpha-cell as target for type 2 diabetes therapyMikkel Christensen, Jonatan I Bagger, Tina Vilsbøll, et al.Current Diabetes Reports|October 27, 2014
Glucagon and type 2 diabetes: the return of the alpha cellAsger Lund, Jonatan I Bagger, Mikkel Christensen, et al.Basic & Clinical Pharmacology & Toxicology|August 21, 2015
Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor TreatmentHeidi Storgaard, Jonatan I Bagger, Filip K Knop, et al.American Journal of Physiology. Endocrinology and Metabolism|March 10, 2011
The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetesAsger Lund, Tina Vilsbøll, Jonatan I Bagger, et al.Frontiers in Physiology|September 23, 2022
A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experimentVijaya Subramanian, Jonatan I Bagger, Jens J Holst, et al.Medical Hypotheses|November 9, 2015
Involvement of steatosis-induced glucagon resistance in hyperglucagonaemiaMalte P Suppli, Asger Lund, Jonatan I Bagger, et al.Frontiers in Endocrinology|January 25, 2021
Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver FatDavid S Mathiesen, Asger Lund, Tina Vilsbøll, et al.Diabetologia|June 1, 2014
Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individualsJonatan I Bagger, Filip K Knop, Asger Lund, et al.Pageof 5